Working… Menu

Ponatinib for FLT3-ITD Acute Myelogenous Leukemia (PONATINIB-AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02428543
Recruitment Status : Recruiting
First Posted : April 29, 2015
Last Update Posted : November 24, 2017
Information provided by (Responsible Party):
Philippe ROUSSELOT, Versailles Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2017
Estimated Study Completion Date : September 2020